Crispr Therapeutics price target lowered to $110 from $123 at Chardan

Chardan lowered the firm’s price target on Crispr Therapeutics to $110 from $123 and keeps a Buy rating on the shares after its Q2 results. The firm is updating its model based on the probability-adjusted modeling of key franchises, raising its FY23 EPS view to ($4.65) from ($5.73) but cutting its FY24 view to ($8.21) from $6.72).